trending Market Intelligence /marketintelligence/en/news-insights/trending/iXB4h1qnM4_bPCL8o6uuTg2 content esgSubNav
In This List

AstraZeneca's Tagrisso fast-tracked for 1st-line treatment of lung cancer

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet

Blog

Insight Weekly: Stocks limp into 2023; GCC banks set for rebound; deep-sea mining faces pushback

Infographic

Infographic: The Big Picture 2023 Sustainability Outlook

Blog

The Big Picture for 2023: Assessing Investment Trends and the Impact of Investor Activism


AstraZeneca's Tagrisso fast-tracked for 1st-line treatment of lung cancer

AstraZeneca PLC's Tagrisso was granted breakthrough therapy designation by the U.S. Food and Drug Administration for first-line treatment of patients with a certain type of lung cancer.

The FDA granted the designation based on data from the phase 3 FLAURA trial of Tagrisso versus standard-of-care therapy in previously-untreated patients.

Tagrisso, or osimertinib, is currently approved in over 50 countries, including the U.S. and EU, as a second-line of treatment for patients with locally advanced or epidermal growth factor receptor-mutated nonsmall cell lung cancer.